GSK & Avalon Ventures: Collaborating to invest $495 million in early stage life science companies




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: GSK & Avalon Ventures: Collaborating to invest $495 million in early stage life science companies
Released on: May 10, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Jay Lichter of Avalon Ventures & Lon Cardon of GSK.
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Jay Lichter of Avalon Ventures & Lon Cardon of GSK.
In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Jay Lichter of Avalon Ventures & Lon Cardon of GSK.
Jay Lichter and Lon Cardon
Avalon Ventures
Avalon Ventures
Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences. We are passionate about backing talented entrepreneurs seeking to build market-leading companies. Our current venture fund of $200 million was launched in August 2012 and continues our tradition of great relationships, companies and results spanning 30 years and ten funds.